Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs

참고문헌 (45)

1. Ferrara N, "Angiogenesis as a therapeutic target", 438, pp.967~974 (2005)
2. Kerbel RS, "Antiangiogenic therapy: a universal chemosensitization strategy for cancer?", 312, pp.1171~1175
3. Kerbel RS, "Antiangiogenic basis of low-dose metronomic chemotherapy", 4, pp.423~436 (2004)
4. Miller KD, "Redefining the target: chemotherapeutics as antiangiogenics", 19, pp.1195~1206 (2001)
5. Browder T, "Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer", 60, pp.1878~1886 (2000)
6. Colleoni M, "Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels", 13, pp.73~80 (2002)
7. Emmenegger U, "A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens", 64, pp.3994~4000 (2004)
8. Klement G, "Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity", 105, pp.15~24 (2000)
9. Pietras K, "A multitargeted, metronomic, and maximum-tolerated dose chemo-switch regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer", 23(mic), pp.939~952 (2005)
10. du Manoir JM, "Strategies for delaying or treating in vivo acquired resistance to trastuzumab (Herceptin) in human breast cancer xenografts", 12, pp.904~916 (2006)
11. Hermans IF, "Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model", 63, pp.8408~8413 (2003)
12. Bottini A, "Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients", 24, pp.3623~3628 (2006)
13. Bocci G, "Cyclophosphamide-methotrexate metronomic chemotherapy for the palliative treatment of metastatic breast cancer", 16, pp.1243~1252 (2004)
14. Kato H, "A randomized trial of adjuvant chemotherapy with uracil- tegafur for adenocarcinoma of the lung", 350, pp.1713~1721 (2004)
15. "Tannock IF. Population kinetics of carcinoma cells and fibroblasts in a transplanted mouse mammary tumor. Cancer Res. 1970;30", pp.2470~6
16. Eberhard A, "Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies", 60, pp.1388~1393 (2000)
17. "Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays. 1991;13", pp.31~6
18. Bertolini F, "Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells", 63, pp.4342~4346 (2003)
19. Furstenberger G, "Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy or primary breast cancer", 94, pp.524~531 (2006)
20. Hudis CA, "Clinical implications of antiangiogenic therapies", 19, pp.26~31 (2005)
21. Asahara T, "Isolation of putative progenitor endothelial cells for angiogenesis", 275, pp.964~967 (1997)
22. Shaked Y, "Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis", 7, pp.101~111 (2005)
23. Bertolini F, "The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification", 6, pp.835~845 (2006)
24. Garcia-Barros M, "Tumor response to radiotherapy regulated by endothelial cell apoptosis", 300, pp.1155~1159 (2003)
25. Spring H, "Chemokines direct endothelial progenitors into tumor neovessels", 102, pp.18111~18116 (2005)
26. Shaked Y, "Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors", 313, pp.1785~1787 (2006)
27. Tozer GM, "Disrupting tumour blood vessels", 5, pp.423~435 (2005)
28. Ghiringhelli F, "Metronomic cyclophosphamide regimen selectively depletes CD4(+)CD25(+) regulatory T cells and restores T and NK effector functions in end stage cancer patients", 56, pp.641~648 (2006)
29. Shaked Y, "The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity", 106, pp.3058~3061 (2005)
30. Ng SS, "Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel", 12, pp.4331~4338 (2006)
31. Munoz R, "Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy", 66, pp.3386~3391 (2006)
32. Mancuso P, "Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy", 108, pp.452~459 (2006)
33. Man S, "Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water", 62, pp.2731~2735 (2002)
34. Kerbel RS, "Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived - but they can be improved", 2, pp.108~113 (2003)
35. Man S, "On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing" (2007)
36. Rocca A, "Metronomic chemotherapy with capecitabine and oral cyclophosphamide in combination with bevacizumab in metastatic breast cancer (mbc): evidence of activity of an antianigogenic treatment" (2007)
37. Buckstein R, "High dose celecoxib and metronomic low dose cyclophosphamide is effective and safe therapy in patients with relapsed and refractory aggressive histology NHL", 12, pp.5190~5198 (2006)
38. Garcia AA, "Phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian cancer. A study of the California, Chicago and Princess Margaret Hospital Phase II Consortia" (2007), in press
39. Glode LM, "Metronomic therapy with cyclophosphamide and dexamethasone for prostate cancer", 98, pp.1643~1648 (2003)
40. Orlando L, "Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer", 17, pp.961~967 (2006)
41. Vogt T, "Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors", 98, pp.2251~2256 (2003)
42. Kong DS, "A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma", 16, pp.1117~1121 (2006)
43. Reichle A, "Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma", 101, pp.2247~2256 (2004)
44. Buckstein R, "High-dose celecoxib and metronomic low-dose cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma", 12, pp.5190~5198 (2006)
45. Young SD, "Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors", 12, pp.3092~3098 (2006)

관련 논문AI추천